| Literature DB >> 28587076 |
Simona Concilio1, Lucia Sessa2, Anna Maria Petrone3,4, Amalia Porta5, Rosita Diana6, Pio Iannelli7, Stefano Piotto8.
Abstract
Some novel (phenyl-diazenyl)phenols 3a-g were designed and synthesized to be evaluated for their antimicrobial activity. A previously synthesized molecule, active against bacteria and fungi, was used as lead for modifications and optimization of the structure, by introduction/removal or displacement of hydroxyl groups on the azobenzene rings. The aim of this work was to evaluate the consequent changes of the antimicrobial activity and to validate the hypothesis that, for these compounds, a plausible mechanism could involve an interaction with protein receptors, rather than an interaction with membrane. All newly synthesized compounds were analyzed by ¹H-NMR, DSC thermal analysis and UV-Vis spectroscopy. The in vitro minimal inhibitory concentrations (MIC) of each compound was determined against Gram-positive and Gram-negative bacteria and Candida albicans. Compounds 3b and 3g showed the highest activity against S. aureus and C. albicans, with remarkable MIC values of 10 µg/mL and 3 µg/mL, respectively. Structure-activity relationship studies were capable to rationalize the effect of different substitutions on the phenyl ring of the azobenzene on antimicrobial activity.Entities:
Keywords: QSAR; antimicrobial; azo-compound; synthesis
Mesh:
Substances:
Year: 2017 PMID: 28587076 PMCID: PMC6152751 DOI: 10.3390/molecules22060875
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Substituted-(phenyldiazenyl)phenol derivatives 3a–g.
Scheme 1Synthetic route for compounds 3a–d.
Scheme 2Synthetic route for compounds 3e–g.
Thermal and optical properties of compounds 3a–g.
| Molecule | Thermal Characterization | Optical Characterization | ||||
|---|---|---|---|---|---|---|
| Tm (°C) | ∆Hm (J/g) | Tc (°C) | ∆Hc (J/g) | λmax (nm) | εmax (L mol−1 cm−1) | |
|
| 114.4 | 5.7 | - | - | 358 | 9300 |
|
| 87.7 | 78.0 | - | - | 344 | 18,300 |
|
| 128.3 | 98.1 | 94.6 | 92.1 | 360 | 14,000 |
|
| 89.3 | 86.1 | - | - | 354 | 11,400 |
|
| 162.0 | 149.8 | - | - | 344 | 14,470 |
|
| 147.3 | 123.3 | 110.6 | 104.5 | 355 | 14,200 |
|
| 158.7 | 139.4 | 90.7 | 83.7 | 358 | 14,350 |
Tm = melting temperature, from DSC analysis, 10 °C/min, nitrogen flow; Tc = crystallization temperature, from DSC cooling run; Instrument error ±0.5 °C. ∆Hm/∆Hc = melting/crystallization enthalpy, evaluated by integration of the peak. Experimental error ±5%. λmax = wavelength at the principal absorption maximum, εmax = molar extinction coefficient at absorption maximum.
Antimicrobial and antifungal activity of A4 analogues. Geometric mean MICs (µg/mL) after 24 h.
| Molecule |
|
|
|
|---|---|---|---|
| MIC50 | MIC2 | ||
|
| 15 (MIC100 20 *) | >35 | 15 (MIC0 17 *) |
|
| 30 | >35 | 25 |
|
| 7 (MIC100 10) | >35 | 10 |
|
| >35 | >35 | >35 |
|
| >35 | >35 | >35 |
|
| 25 | >35 | 20 |
|
| 25 | >35 | 25 |
|
| 7 (MIC100 20) | >35 | MIC0 3 |
MIC50: Minimum Inhibitory Concentration required to inhibit the growth of 50% of bacteria. MIC100: Minimum Inhibitory Concentration required to inhibit the growth of 100% of bacteria. MIC2: Minimum Inhibitory Concentration required to inhibit the growth of 50% of fungus. MIC0: Minimum Inhibitory Concentration required to inhibit the growth of 100% of fungus. The values are the geometric mean of at least three determinations. * Data from ref. [9].
Figure 2Inhibition of hyphae formation in Candida albicans at different concentrations (μg/mL) of A4 and 3g (20× optical zoom).
Comparison of experimental and calculated antimicrobial activity against S. aureus.
| Molecule | MIC50 Experimental (μg/mL) | Actual Values for C:1/MIC50 | ALogP | Equation (1): Predicted Values | Equation (1): Residual Values | MIC50 Predicted |
|---|---|---|---|---|---|---|
|
| 15 | 0.067 | 2.8 | 0.0513 | 0.0154 | 19 |
|
| 30 | 0.033 | 2.8 | 0.0520 | −0.0187 | 19 |
|
| 7 | 0.143 | 5.0 | 0.1460 | −0.0030 | 7 |
|
| 80 * | 0.013 | 3.0 | 0.0214 | −0.0089 | 50 |
|
| 80 * | 0.013 | 7.2 | 0.0357 | −0.0232 | 30 |
|
| 25 | 0.040 | 1.8 | 0.0452 | −0.0052 | 22 |
|
| 25 | 0.040 | 0.7 | 0.0909 | −0.0509 | 11 |
|
| 7 | 0.143 | 3.2 | 0.0950 | 0.0479 | 10 |
|
| 17 | 0.059 | 0.8 | 0.0756 | −0.0168 | 13 |
|
| 15 | 0.067 | 2.6 | 0.0822 | 0.0155 | 12 |
|
| 14 | 0.071 | 0.2 | 0.0699 | 0.0015 | 14 |
|
| 18 | 0.056 | 4.3 | 0.0625 | −0.0069 | 16 |
|
| 80 * | 0.013 | 0.3 | 0.0142 | −0.0017 | 70 |
|
| 80 * | 0.013 | 1.1 | 0.0142 | −0.0017 | 70 |
* Molecules that did not show activity for concentration larger than 35 µg/mL, have been arbitrarily assigned to 80 to perform the GFA.
Validation of the genetic function results.
| Parameters | Value |
|---|---|
| Friedman LOF | 0.00302 |
| R-squared | 0.802 |
| Adjusted R-squared | 0.766 |
| Cross validated R-squared | 0.654 |
| Significant Regression | Yes |
| Significance-of-regression F-value | 22.321 |
| Critical SOR F-value (95%) | 5.2341 |
| Replicate points | 0 |
| Computed experimental error | 0.000 |
| Number or points for Lack-of-fit test | 11 |
| Min expt. error for non-significant LOF (95%) | 0.0201 |